{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:54Z","timestamp":1763754654728,"version":"3.45.0"},"reference-count":30,"publisher":"Oncology Nursing Society (ONS)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.1188\/25.cjon.303-312","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:19:37Z","timestamp":1755019177000},"source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children\u2019s Oncology Group"],"prefix":"10.1188","member":"1302","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"1","unstructured":"Amgen. (2024). BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use [Package insert]. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Blincyto\/blincyto_pi_hcp_english.pdf"},{"key":"2","unstructured":"Angiolillo, A., Schore, R., Devidas, M., Lu, X., Rabin, K.R., Zweidler-McKay, P.A., . . . Hunger, S.P. (2017). Intensification of oral methotrexate is not superior to standard methotrexate dosing during maintenance in children with National Cancer Institute (NCI) standard-risk B acute lymphoblastic leukemia (SR B-ALL): A report from Children\u2019s Oncology Group (COG) study AALL0932. Blood, 130(Suppl. 1), 140."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Attarbaschi, A., Mann, G., Zimmermann, M., Bader, P., Barisone, E., Basso, G., . . . Rizzari, C. (2020). Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: Long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia, 34(6), 1694\u20131700. https:\/\/doi.org\/10.1038\/s41375-019-0670-y","DOI":"10.1038\/s41375-019-0670-y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Bernhardt, M.B., Militano, O., Honeyford, L., & Zupanec, S. (2021). Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges. Journal of Oncology Pharmacy Practice, 27(2), 376\u2013388. https:\/\/doi.org\/10.1177\/1078155220979047","DOI":"10.1177\/1078155220979047"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bhojwani, D., Bansal, R., & Wayne, A.S. (2021). Managing therapy-associated neurotoxicity in children with ALL. Hematology. American Society of Hematology. Education Program, 2021(1), 376\u2013383. https:\/\/doi.org\/10.1182\/hematology.2021000269","DOI":"10.1182\/hematology.2021000269"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Brown, P.A., Ji, L., Xu, X., Devidas, M., Hogan, L.E., Borowitz, M.J., . . . Loh, M.L. (2021). Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA, 325(9), 833\u2013842. https:\/\/doi.org\/10.1001\/jama.2021.0669","DOI":"10.1001\/jama.2021.0669"},{"key":"7","unstructured":"Children\u2019s Oncology Group. (2023). Guideline for the management of fever and neutropenia in children with cancer and\/or undergoing hematopoietic stem-cell transplantation. https:\/\/www.childrensoncologygroup.org\/docs\/default-source\/pdf\/cog_sc_fn_guideline_document.pdf?sfvrsn=4ddadbb1_2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Conter, V., Valsecchi, M.G., Cario, G., Zimmermann, M., Attarbaschi, A., Stary, J., . . . Schrappe, M. (2024). Four additional doses of PEG-L-asparaginase during the consolidation phase in the AIEOP-BFM ALL 2009 protocol do not improve outcome and increase toxicity in high-risk ALL: Results of a randomized study. Journal of Clinical Oncology, 42(8), 915\u2013926. https:\/\/doi.org\/10.1200\/JCO.23.01388","DOI":"10.1200\/JCO.23.01388"},{"key":"9","doi-asserted-by":"crossref","unstructured":"DePadova, S., Howlett, C., & Rivera, K. (2016). A multidisciplinary approach to standardizing processes for blinatumomab administration. Clinical Journal of Oncology Nursing, 20(5), 466\u2013469. https:\/\/doi.org\/10.1188\/16.CJON.466-469","DOI":"10.1188\/16.CJON.466-469"},{"key":"10","unstructured":"European Medicines Agency. (2024). Annex I: Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blincyto-epar-product-information_en.pdf"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Gupta, S., Rau, R.E., Kairalla, J.A., Rabin, K.R., Wang, C., Angiolillo, A.L., . . . Loh, M.L. (2024). Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. New England Journal of Medicine, 392(9), 875\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa2411680","DOI":"10.1056\/NEJMoa2411680"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Herr, M.M., Chen, G.L., Ross, M., Jacobson, H., McKenzie, R., Markel, L., . . . McCarthy, P.L. (2020). Identification of neurotoxicity after chimeric antigen receptor (CAR) T cell infusion without deterioration in the Immune Effector Cell Encephalopathy (ICE) score. Biology of Blood and Marrow Transplantation, 26(11), E271\u2013E274. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.031","DOI":"10.1016\/j.bbmt.2020.07.031"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Hunger, S.P., & Mullighan, C.G. (2015). Acute lymphoblastic leukemia in children. New England Journal of Medicine, 373(16), 1541\u20131552. https:\/\/doi.org\/10.1056\/NEJMra1400972","DOI":"10.1056\/NEJMra1400972"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kirkwood, A.A., Goulden, N., Moppett, J., Samarasinghe, S., Mee, J., Hough, R., . . . Vora, A. (2022). High dose methotrexate does not reduce the risk of CNS relapse in children and young adults with acute lymphoblastic leukaemia and lymphoblastic lymphoma. Results of the randomised phase III study UKALL 2011. Blood, 140(Suppl. 1), 516\u2013518. https:\/\/doi.org\/10.1182\/blood-2022-160129","DOI":"10.1182\/blood-2022-160129"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Li, A.M., Rabin, K.R., Kairalla, J., Wang, C., Devidas, M., Militano, O., . . . Rau, R.E. (2021). Blinatumomab associated seizure risk in patients with Down syndrome and B-lymphoblastic leukemia: An interim report from Children\u2019s Oncology Group (COG) study AALL1731. Blood, 138(Suppl. 1), 2304. https:\/\/doi.org\/10.1182\/blood-2021-148967","DOI":"10.1182\/blood-2021-148967"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Litzow, M.R., Sun, Z., Mattison, R.J., Paietta, E.M., Roberts, K.G., Zhang, Y., . . . Tallman, M.S. (2024). Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. New England Journal of Medicine, 391(4), 320\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa2312948","DOI":"10.1056\/NEJMoa2312948"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Maloney, K.W., Devidas, M., Wang, C., Mattano, L.A., Friedmann, A.M., Buckley, P., . . . Winick, N.J. (2020). Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: Results of Children\u2019s Oncology Group trial AALL0331. Journal of Clinical Oncology, 38(6), 602\u2013612. https:\/\/doi.org\/10.1200\/JCO.19.01086","DOI":"10.1200\/JCO.19.01086"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Marrapodi, M.M., Mascolo, A., di Mauro, G., Mondillo, G., Pota, E., & Rossi, F. (2022). The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Frontiers in Pediatrics, 10, 929122. https:\/\/doi.org\/10.3389\/fped.2022.929122","DOI":"10.3389\/fped.2022.929122"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Mattano, L.A., Devidas, M., Friedmann, A.M., Raetz, E.A., Loh, M., Buckley, P., . . . Maloney, K. (2014). Outstanding outcome for children with standard risk-low (SR-low) acute lymphoblastic leukemia (ALL) and no benefit to intensified peg-asparaginase (PEG-ASNase) therapy: Results of Children\u2019s Oncology Group (COG) study AALL0331. Blood, 124(21), 793. https:\/\/doi.org\/10.1182\/blood.V124.21.793.793","DOI":"10.1182\/blood.V124.21.793.793"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Montgomery, K.E., Zupanec, S., Yun, C., Okada, M., Kubaney, H., Feehily, E., & Withycombe, J.S. (2024). A quality approach to blinatumomab delivery in pediatric oncology: A Children\u2019s Oncology Group study. Journal of Pediatric Hematology\/Oncology Nursing, 41(5), 324\u2013335. https:\/\/doi.org\/10.1177\/27527530241267303","DOI":"10.1177\/27527530241267303"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Moody, J., Barker, P.J., Sciasci, J., Pauley, J.L., Bragg, A., McMillan, C., . . . Swanson, H.D. (2024). Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission. Pediatric Blood and Cancer, 71(10), e31223. https:\/\/doi.org\/10.1002\/pbc.31223","DOI":"10.1002\/pbc.31223"},{"key":"22","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. (2017). Common Terminology Criteria for Adverse Events [v.5.0]. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"23","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. (2025, April 16). SEER*Explorer. National Institutes of Health. Retrieved April 29, 2025, from https:\/\/seer.cancer.gov\/statistics-network\/explorer"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Oranges, K., Windawi, S., Powell, S., Dallago, D., Escobar, N., & Rheingold, S.R. (2020). How we infuse blinatumomab. Pediatric Blood and Cancer, 67(9), e28541. https:\/\/doi.org\/10.1002\/pbc.28541","DOI":"10.1002\/pbc.28541"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Szoch, S., Boord, C., Duffy, A., & Patzke, C. (2018). Addressing administration challenges associated with blinatumomab infusions: A multidisciplinary approach. Journal of Infusion Nursing, 41(4), 241\u2013246. https:\/\/doi.org\/10.1097\/NAN.0000000000000283","DOI":"10.1097\/NAN.0000000000000283"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Traube, C., Silver, G., Kearney, J., Patel, A., Atkinson, T.M., Yoon, M.J., . . . Greenwald, B. (2014). Cornell Assessment of Pediatric Delirium: A valid, rapid, observational tool for screening delirium in the PICU. Critical Care Medicine, 42(3), 656\u2013663. https:\/\/doi.org\/10.1097\/CCM.0b013e3182a66b76","DOI":"10.1097\/CCM.0b013e3182a66b76"},{"key":"27","doi-asserted-by":"crossref","unstructured":"van der Sluis, I.M., de Lorenzo, P., Kotecha, R.S., Attarbaschi, A., Escherich, G., Nysom, K., . . . Pieters, R. (2023). Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. New England Journal of Medicine, 388(17), 1572\u20131581. https:\/\/doi.org\/10.1056\/NEJMoa2214171","DOI":"10.1056\/NEJMoa2214171"},{"key":"28","doi-asserted-by":"crossref","unstructured":"von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., . . . Gore, L. (2016). Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Journal of Clinical Oncology, 34(36), 4381\u20134389. https:\/\/doi.org\/10.1200\/JCO.2016.67.3301","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Withycombe, J.S., Kubaney, H.R., Okada, M., Yun, C.S., Gupta, S., Bloom, C., . . . Zupanec, S. (2024). Delivery of care for pediatric patients receiving blinatumomab: A Children\u2019s Oncology Group study. Cancer Nursing, 47(6), 451\u2013459. https:\/\/doi.org\/10.1097\/NCC.0000000000001309","DOI":"10.1097\/NCC.0000000000001309"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Wo, S., Levavi, H., Mascarenhas, J., Kremyanskaya, M., Navada, S., Bar-Natan, M., & Kim, S.S. (2022). Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Research, 57(2), 135\u2013143. https:\/\/doi.org\/10.5045\/br.2022.2021163","DOI":"10.5045\/br.2022.2021163"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/publications-research\/cjon\/29\/4\/blinatumomab-administration-pediatric-b-lineage-all-expert","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:47:35Z","timestamp":1763754455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/29\/4\/blinatumomab-administration-pediatric-b-lineage-all-expert"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1188\/25.cjon.303-312","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}